KYNB stock news · Kyntra Bio, Inc.
Get alerts for KYNB
Follow Kyntra Bio, Inc. (KYNB) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for KYNBFree on the App Store and Google Play, or on the web.
Kyntra Bio, Inc. shared its Q3 2026 results, showing a profit of $0.2 million and plans for a new drug trial.
NeutralKyntra Bio cut its payment cap by $60 million and ended 2 programs after weak results. Savings and a failed trial, plus funding needed for Phase 3, leave a mixed picture.
Kyntra Bio, Inc. has been told it might be removed from Nasdaq for not following the rules.
Bad for KYNBKyntra Bio has not met Nasdaq's continued-listing rules, and staff plans to delist its stock. A hearing keeps it listed for now, but the risk remains serious.
Kyntra Bio, Inc. says some directors and officers are leaving, while new ones are being chosen.
NeutralKyntra Bio added a director with biopharma deal experience as a longtime director left. The changes appear balanced and do not clearly shift the company's prospects.